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BACKGROUND: ALCAM (activated leucocyte cell adhesion molecule, synonym CD166) is a cell adhesion molecule, which belongs to
the Ig superfamily. Disruption of the ALCAM-mediated adhesiveness by proteolytic sheddases such as ADAM17 has been suggested
to have a relevant impact on tumour invasion. Although the expression of ALCAM is a valuable prognostic and predictive marker in
several types of epithelial tumours, its role as a prognostic marker in pancreatic cancer has not yet been reported.
METHODS: In this study, paraffin-embedded samples of 97 patients with pancreatic cancer undergoing potentially curative resection
were immunostained against ALCAM, ADAM17 and CK19. Expression of ALCAM and ADAM17 was semiquantitatively evaluated
and correlated to clinical and histopathological parameters.
RESULTS: We could show that in normal pancreatic tissue, ALCAM is predominantly expressed at the cellular membrane, whereas in
pancreatic tumour cells, it is mainly localised in the cytoplasm. In addition, univariate and multivariate analyses show that increased
expression of ALCAM is an adverse prognostic factor for recurrence-free and overall survival. Overexpression of ADAM17 in
pancreatic cancer, however, failed to be a significant prognostic marker and was not coexpressed with ALCAM.
CONCLUSIONS: Our findings support the hypothesis that the disruption of ALCAM-mediated adhesiveness is a relevant step in
pancreatic cancer progression. Moreover, ALCAM overexpression is a relevant independent prognostic marker for poor survival and
early tumour relapse in pancreatic cancer.
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Pancreatic cancer is one of the most aggressive tumours in humans.
It is the fourth leading cause of cancer death in females and the fifth
leading cause in males worldwide (Jemal et al,2 0 0 8 ) .D e s p i t es o m e
progress in the medical treatment, surgical resection remains the
only chance for cure in localised stages. However, even in the small
subset of approximately 15–20% of patients with pancreatic cancer,
who are eligible to curative resection, cancer-related death is still
very high. Currently, lymph node status is one of the most
important independent prognostic markers in patients who undergo
resection (Geer and Brennan, 1993; Delcore et al,1 9 9 6 ;H e l l a net al,
2008). Further clinical and pathological prognostic parameters are
tumour typing, differentiation grade and size (Geer and Brennan,
1993); however, this information is currently not used for clinical
management of the patients. Adjuvant chemotherapy is commonly
offered to all patients with resected pancreatic cancer (Neoptolemos
et al, 2001); however, only a certain subgroup of patients will benefit
from this treatment. Better definition of the patient’s individual
prognosis might allow a more individualised adjuvant therapy.
Therefore, in recent years, the focus has been shifted to define new
molecular prognostic markers to gain such prognostic information
and to select patient subgroups that might benefit from specific
treatment algorithms.
ALCAM (activated leucocyte cell adhesion molecule, synonym
CD166) belongs to the Ig superfamily and mediates both
heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM)
cell–cell interactions (Swart, 2002). It is considered a prognostic
marker in melanoma (van Kempen et al, 2000), prostate cancer
(Kristiansen et al, 2005), breast cancer (King et al, 2004; Weichert
et al, 2004; Burkhardt et al, 2006), colorectal cancer (Weichert
et al, 2004), bladder cancer (Tomita et al, 2003), oesophageal
squamous cell carcinoma (Verma et al, 2005) and ovarian cancer
(Mezzanzanica et al, 2008). However, these data are quite
inconsistent. In some tumour types membranous expression is
associated with worse prognosis (Weichert et al, 2004), whereas in
other tumour types cytoplasmic localisation of ALCAM is an
adverse prognostic parameter (Burkhardt et al, 2006). In addition,
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sincreased (Tomita et al, 2003; Weichert et al, 2004; Kristiansen
et al, 2005; Verma et al, 2005; Burkhardt et al, 2006) as well as
reduced (King et al, 2004; Mezzanzanica et al, 2008) expression of
ALCAM has been correlated with poor prognosis, depending on
the tumour type.
Recently, Bech-Serra et al (2006) have shown that ADAM17 acts
as a proteolytic sheddase of ALCAM. Rosso et al (2007) observed
that this process is involved in the motility of epithelial ovarian
carcinoma cells. They postulated that the disruption of the
ALCAM-mediated adhesiveness is a relevant step, which increased
the invasiveness of tumour cells.
The aim of our study was to evaluate the prognostic significance
of ALCAM in pancreatic cancer. In addition, based on the
observations of Bech-Serra et al and Rosso et al, we analysed its
correlation with ADAM17.
Here, we show that overexpression of ALCAM is an adverse
prognostic factor for recurrence-free and overall survival (OS) in
pancreatic cancer. However, despite its important role in tumour
invasion and progression in pancreatic cancer (Ringel et al, 2006)
and other types of tumours (Arribas et al, 2006; Mochizuki and
Okada, 2007), immunohistochemical expression of ADAM17
correlates significantly neither with clinical and pathological data
nor with ALCAM expression in pancreatic cancer.
MATERIALS AND METHODS
Patients
Paraffin-embedded tumour samples were analysed from 97
patients aged 31–82 years (mean 63, median 65; 44 female, 53
male), who were diagnosed with a primary ductal adenocarcinoma
of the pancreas and who underwent tumour resection at the
Department of Surgery, University Hospital Heidelberg between
2002 and 2005. The median follow-up period was 18.3 months.
A written informed consent had been obtained before resection
Figure 1 CD166 expression in pancreatic cancer and normal pancreatic tissue. (A) Pancreatic tumour cells displaying a CD166 intensity of 0 next to
remnant pancreatic islet cells with an intensity of 3. (B) Pancreatic tumour cells displaying a CD166 intensity of 1 next to a nerve with a CD166 intensity of 2
and remnant pancreatic islet cells with an intensity of 3. (C) Pancreatic tumour cells displaying a CD166 intensity of 2. (D) Pancreatic tumour cells displaying
a CD166 intensity of 3 next to remnant pancreatic islet cells with an intensity of 3. (E) Pancreatic tumour cells displaying membranous expression of CD166.
(F) Normal pancreatic tissue with membranous staining. Original magnification,  400.
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sfrom all patients regarding tissue sampling; the tissue sampling
and the analyses regarding potential prognostic markers were
approved by the local ethics committee. No neoadjuvant radio- or
chemotherapy was applied before surgical resection to any patient.
A total of 60 patients underwent a pylorus-sparing pancreatico-
duodenectomy, 11 patients a classic pancreatico-duodenectomy,
17 patients a distal pancreatectomy and 9 patients a total
pancreatectomy. According to the AJCC classification, there were
18 patients with tumour stage II, 74 patients with tumour stage III
and 5 patients with tumour stage IV. In total, 88 cases were
resected R0 and 9 cases were resected R1. Patients with R2
resections were not included in this study. It is to be noted that as
all patients included in this study were operated between 2002 and
2005, evaluation of the R status had been still carried out by
nonstandardised protocols and not according to the recently
suggested new standardised protocols, revealing a significantly
higher number of R1 resections (Esposito et al, 2008).
After resection 70 patients received adjuvant chemotherapy.
This included 35 patients treated with gemcitabine, 22 treated with
5-fluorouracil and 13 subjected to a combined radiochemotherapy.
In total, 19 patients did not receive any adjuvant treatment; in 8
cases the type of postoperative treatment was unknown.
Immunohistochemistry
Comparative studies of ALCAM, ADAM17 and CK19 were carried
out on sequential serial sections. Immunohistochemical staining
was carried out on 4-mm sections of formalin-fixed, paraffin-
embedded tumour samples. The archival tissue array blocks were
freshly cut, sections were mounted on SUPERFROST PLUS
microscope slides (Menzel, Braunschweig, Germany) and incu-
bated at 371C overnight. Sections were deparaffinised in xylene,
rehydrated in a graded series of ethanol and washed with 1moll
 1
phosphate-buffered saline (PBS). For heat-induced antigen retrie-
val for ALCAM and ADAM17, slides were boiled in a microwave
oven for 5min (pH 6.0, 0.94ml Antigen Unmasking Solution per
100ml distilled water (Vector Laboratories, Inc., Burlingame, CA,
USA)) thrice and allowed to cool down at room temperature for at
least 20min. Antigen-retrieval for CK19 staining was achieved by
preincubating samples with Pronase E for 5min. After immersing
slides in a 3.0% hydrogen peroxidase solution in methanol for
20min to inhibit endogenous peroxidase activity, nonspecific
binding sites were blocked by preincubation with 10% normal goat
serum (Vector Laboratories) in 1moll
 1 PBS for 30min at room
temperature for ALCAM- and CK19 staining. Nonspecific binding
in sections for ADAM17 staining was blocked using an Avidin/
Biotin Blocking Kit (Vector Laboratories). Slides were incubated
overnight at 41C with primary mouse monoclonal anti-ALCAM
antibody (clone MOG/07; Novocastra, Newcastle upon Tyne, UK)
at a dilution of 1:100 or with rabbit polyclonal anti-ADAM17
Figure 2 ADAM17 expression in pancreatic cancer. (A) Pancreatic tumour cells displaying an ADAM17 intensity of 0. (B) Pancreatic tumour cells
displaying an ADAM17 intensity of 1. (C) Pancreatic tumour cells displaying an ADAM17 intensity of 2. (D) Pancreatic tumour cells displaying an ADAM17
intensity of 3. Original magnification,  400.
Table 1 ALCAM displays a differential cellular expression pattern in
pancreatic cancer and normal peritumoral pancreatic tissue (w
2-test)
Cellular localisation
Negative
staining
Cytoplasmic
staining
Membranous
staining P-value
Pancreatic cancer
(n¼97)
41 50 6
Normal pancreatic
tissue (n¼60)
12 0 48 0.0001
ALCAM¼activated leucocyte cell adhesion molecule.
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santibody (Anti-TACE (807–823); Calbiochem, La Jolla, CA, USA)
at a dilution of 1:50 in a dilution buffer (Antibody Diluent; Dako
A/S, Glostrup, Denmark). Mouse monoclonal anti-human Cyto-
keratin 19 (clone RCK108; DakoCytomation A/S) was diluted
1:100 in dilution buffer and incubated at room temperature for
1h. To eliminate nonspecific staining resulting from endogenous
avidin–biotin activity, slides were incubated with EnVisionþ
System (DakoCytomation A/S) (EnVision anti-mouse for ALCAM-
and CK19-, anti-rabbit for ADAM17 staining) for 30min at room
temperature. Immunoreactions were developed and target antigens
were detected using AEC Substrate Chromogen (DakoCytomation
A/S) according to the instructions of the manufacturer. Finally,
sections were counterstained with haematoxylin, dehydrated in
graded concentrations of ethanol and mounted. The staining
intensity of each slide was scored as absent: 0, weak: 1, medium: 2
and strong: 3 as described before (Kristiansen et al, 2003) on a
blind basis by three independent researchers (CK, HW, NM) and
two pathologists (CM, FB). Besides, for ALCAM, clinical specimen
were characterised as membranous-positive or as non-membra-
nous staining.
Statistical analysis
w
2-test were used to examine the statistical significance of ALCAM-
and ADAM17 expression in pancreatic cancer in comparison with
clinical and pathological parameters. Spearman’s correlation test
was employed to analyse a correlated expression between ALCAM
and ADAM17. Univariate survival analysis was assessed using the
Kaplan–Meier method. Differences in survival curves were
calculated with the log-rank test. Multivariable analysis (Cox
proportional hazards regression model) of OS was carried out on
all covariates that showed significant association with OS in
univariate analysis. P-values of all statistical tests were two-sided
and ro0.05 was considered significant. All statistics were
compiled using the software package SPSS, version 11.0 (SPSS,
Chicago, IL, USA).
RESULTS
Evaluation of specifity of ALCAM and ADAM17
immunohistochemistry
To validate the specificity of immunohistochemical staining
against ALCAM, we repeated immunohistochemistry in 15
representing clinical specimen with two different antibodies
against ALCAM (primary rabbit polyclonal anti-ALCAM antibody,
Atlas Antibodies AB, Stockholm, Sweden and primary mouse
monoclonal anti-ALCAM antibody (clone MOG/07; Novocastra)).
When comparing the immunohistochemical results of the mono-
clonal antibody and the polyclonal antibody in sequential slides,
the expression pattern were identical in 15/15 samples, though the
staining intensity of the polyclonal antibody was weaker than the
staining intensity of the monoclonal antibody (Supplementary
Figure 4a–g). These results confirm the specifity of the anti-
ALCAM staining. For immunohistochemical evaluation of all 97
clinical specimen, we used only the monoclonal antibody (clone
MOG/07), which has been successfully approved before (Weichert
et al, 2004; Mezzanzanica et al, 2008).
Likewise, we carried out immunohistochemistry with two
different antibodies against ADAM17 (clone 1F6, Abnova, Taiwan
and Anti-TACE (807–823); Calbiochem) in 15 representing clinical
specimen. In these 15 representing clinical specimen, the expres-
sion pattern of ADAM17 was similar by the monoclonal antibody
and the polyclonal antibody when compared in sequential slides
(Supplementary Figure 5a–f). Particularly, in none of the samples
stained against ADAM17, we could detect a membranous
expression of ADAM17, as it has been described before (Ringel
et al, 2006).
For immunohistochemical evaluation of all 97 clinical specimens
against ADAM17, we used only the polyclonal antibody, as it
displayed a more intense staining warranting a more diligent
analysis.
ALCAM displays a differential cellular expression pattern
in pancreatic cancer and normal pancreatic tissue
In pancreatic cancer, 56 samples were ALCAM-positive, 41
samples were ALCAM-negative. It is noted that even in specimen,
where immunostaining was absent in tumour cells, endocrine
pancreatic islet cells and nerves were always positive. These
structures served as an internal control. Endocrine islet cells
usually revealed a staining intensity of 3, nerves basically showed a
staining intensity of 2 (Figure 1B). Distribution of staining
intensity in pancreatic cancer was as follows: Intensity 0: 41 cases,
intensity 1: 26 cases, intensity 2: 23 cases and intensity 3: 7 cases.
In total, 50 cases (51%) revealed a cytoplasmic expression
exclusively (Figure 1A–D, Supplementary Figure 1c). In addition
to cytoplasmic expression, membranous positive expression could
be focally detected in six specimens (7%) (Figure 1E). In total, four
of these samples revealed a staining intensity of 2 and two were
scored with a staining intensity of 1. Peritumoral, non-neoplastic
pancreatic tissue was present on the examined slides in 60 samples
adjacent to pancreatic cancer. In 48 of these samples ALCAM was
homogenously expressed in the acinar epithelium (Figure 1F); it is
noted that in all of these samples ALCAM was expressed in the
Table 2 Correlation between CD166 expression and clinical and
pathological parameters (w
2-test)
Characteristics
Number
of cases
CD166
low
CD166
medium
CD166
high P-value
Total 97 67 23 7
Age
oMean 46 33 9 4 0.61
XMean 51 34 14 3
Gender
Female 44 33 10 1 0.20
Male 53 34 13 6
Lymph node status
N0 18 12 4 2 0.78
N1 79 55 19 5
Grading
1 4 4 0 0 0.34
2 5 74 21 2 3
3 3 62 11 1 4
AJCC tumour stage
2 18 12 4 2 0.59
3 7 45 01 9 5
45 5 0 0
R-status
88 59 22 7 0.38
981 0
Survival status after 36 months
a
Deceased 64 40 18 6 0.03
Alive 27 24 3 0
AJCC¼American Joint Committee on Cancer.
aOnly patients with complete follow-
up included. Significantly difference values are indicated in bold.
ALCAM is an independent prognostic marker in pancreatic cancer
C Kahlert et al
460
British Journal of Cancer (2009) 101(3), 457–464 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
scellular membrane. None of the samples of normal pancreatic
tissue showed cytoplasmic staining of ALCAM. The differential
cellular distribution of ALCAM between pancreatic cancer and
corresponding normal pancreatic tissue was highly significant
(P¼0.0001, Table 1).
ADAM17 immunostaining in normal pancreatic tissue and
in pancreatic cancer
A total of 71 pancreatic cancer samples were positive for ADAM17
and 26 samples were negative. In tumour cells, ADAM17 was solely
localised in cytoplasm. Adjacent to pancreatic cancer, we
occasionally observed positive endocrine pancreatic islet cells,
displaying usually an intensity strength of 3. For pancreatic cancer,
staining intensities of ADAM17 were scored as intensity 0: 27
cases, intensity 1: 16 cases, intensity 2: 40 cases and intensity 3: 14
cases (Figure 2A–D, Supplementary Figure 2b–d). In normal
pancreatic tissue, 59 out of 60 cases were scored as negative. This
aberrant expression of ADAM17 in pancreatic cancer compared
with normal pancreatic tissue was highly significant (Po0.0001).
Co-expression analysis between ALCAM and ADAM17
Previous data have shown that ADAM17 is an important sheddase
of ALCAM. Thus, we intended to assess a co-expression between
ADAM17/TACE and ALCAM in pancreatic cancer and to evaluate
a potential co-function. However, diligent immunohistochemical
comparison of sequential sections revealed no significant positive
or negative correlated co-expression. When comparing the
expression intensities (low/medium/high) or the expression
patterns (membranous/cytoplasmic) with each other, statistical
analyses neither showed significant correlation (Spearman’s
correlation coefficient 0.155 P¼0.128 nor contingence coefficient
0.057 P¼0.58).
ALCAM in correlation to clinical and pathological
parameters and prognosis
For statistical analysis, samples with ALCAM immunostaining
were grouped in low (0, 1), medium (2) and high (3) intensity
levels of expression. When comparing the intensity levels to
clinical and pathological parameters, there was a significant
inverse correlation between the grade of intensity and the survival
status of patients after 36 months (w
2 P¼0.03, Table 2). There was
no significant correlation with age, gender, nodal status, grading,
AJCC tumour stage or resection status (Table 2). When analysing
prognostic factors for progression-free and OS, univariate analysis
using the log-rank test confirmed well-known prognostic para-
meters such as lymph node status (P¼0.02), AJCC tumour stage
(P¼0.007) or treatment by adjuvant chemotherapy (P¼0.0001)
(Figure 3D–F Table 3) to be of prognostic relevance in our patient
cohort. Regarding ALCAM expression, median OS was signifi-
cantly reduced in tumours with high intensity level compared with
tumours with medium or low intensity expression levels, (high
expression: median OS 5.6 months, medium expression: median
OS 14.8 months and low expression: median OS 22.8 months,
P¼0.0006, Figure 3A, Table 3). In the same line, progression-free
survival was significantly shorter in tumours displaying high levels
of ALCAM in comparison with medium- and low-expressing
tumours (median progression-free survival times of 7, 8 and 17
months for high, medium and low expression, respectively,
P¼0.008, Table 3). In a further sub-group analysis, the six
patients with partial membranous expression had a significant
shorter median overall (median: 10.9 vs 18.7 months, P¼0.03) and
tumour recurrence-free survival (median: 6 vs 15 months, P¼0.02)
compared with tumours with non-membranous ALCAM staining
(Figure 3B, Table 3). In a multivariate analysis based on the Cox
proportional hazards regression model, we tested the independent
predictive value for all relevant clinical and pathological
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Figure 3 Univariate analysis (log-rank test, Kaplan–Meier curves) of prognostic parameters in pancreatic cancer. (A) Intensity of cytoplasmic expression
of CD166 (P¼0.0006), (B) Membranous vs non-membranous expression of CD166 (P¼0.03), (C) Intensity of cytoplasmic expression of ADAM17
(P¼0.09), (D) Nodal status (P¼0.02), (E) AJCC tumour stage (P¼0.007), (F) adjuvant chemotherapy received vs not received (P¼0.0001).
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sparameters, adjuvant chemotherapy and ALCAM expression. As
we used a non-categorial regression model, we compared low-
ALCAM intensity expression to medium/high-ALCAM intensity
expression. In this analysis, increased ALCAM intensity expression
proved to be an independent prognostic marker for OS
(P¼0.0001) in addition to adjuvant treatment of chemotherapy
(P¼0.0001) and tumour stage (P¼0.007) (Table 4). Lymph node
status was excluded for its linear depending covariance with
tumour stage.
ADAM17 in correlation to clinical and pathological
parameters and prognosis
In analogy to ALCAM expression, we evaluated immunhistochem-
ical staining of ADAM17 expression in pancreatic cancer. Intensity
of staining was scored as low (0, 1), medium (2) and high (3)
expression level and compared with clinical and pathological
parameters. By crosstable-calculation (w
2-test), we found
no significant correlation with age, nodal status, grading, resection
status or AJCC tumour stage (Table 5). Intriguingly, there was a
significant preponderance of medium- and high-expressing
tumour samples in men compared with women (P¼0.03). In an
univariate analysis, intensity of aberrant expression of ADAM17
was not significantly correlated to overall survival (high: median
10.9 months, medium: median 22.8 months and low: median 16.3
months, P¼0.09, Figure 3C, Table 3) or progression-free survival
(high: median 9 months, medium: median 17 months and low:
median 14 months, P¼0.43).
DISCUSSION
Our study for the first time shows that the increased cytoplasmic
expression of ALCAM is an independent prognostic marker for
Table 3 Univariate analysis (log-rank test) of prognostic parameters in pancreatic cancer for median progression-free (PFS) and median overall survival
(OAS)
PFS
a OAS
b
Characteristics Number of cases Time (months) P-value Number of cases Time (months) P-value
Adjuvant chemotherapy
c
Not received 14 7 0.6 19 4.5 0.0001
Received 65 15 69 22.8
Lymph node status
N0 16 24 0.34 17 32.2 0.02
N1 63 12 75 16.3
Grading
1 4 36 0.13 4 37.3 0.33
2 48 15 53 18.5
3 27 11 35 15.5
AJCC tumour stage
2 16 24 0.3 17 32.2 0.01
3 58 12 70 17.7
4 5 6 5 10.9
Resection status
R0 72 24 0.77 83 18.7 0.95
R1 7 15 9 13.6
CD166
Low 57 17 0.008 65 22.8 0.0006
Medium 19 8 21 14.8
High 3 7 6 5.6
Membranous 6 6 0.02 6 10.9 0.03
Non-membranous 73 15 86 18.7
ADAM17
Low 34 14 0.43 40 16.3 0.09
Medium 34 17 40 22.8
High 11 9 12 10.9
AJCC¼American Joint Committee on Cancer
aTotal number of cases only 79, in 12 cases exact time of tumour recurrence could not be specified
bNew: total number of cases
only 92, five cases lost to follow-up),
cType of adjuvant treatment in four cases unknown. Significantly difference values are indicated in bold.
Table 4 Multivariate analysis (Cox proportional hazards regression model, non-categorial) of prognostic parameters for overall survival in pancreatic
cancer
Characteristics b Standard-error Wald d.f. Relative risk 95% CI of relative risk P-value
Adjuvant chemotherapy vs no adjuvant chemotherapy  1.889 0.295 41.127 1 0.151 0.085–0.269 0.0001
CD 166 expression low vs medium/high 1.053 0.270 15.166 1 2.866 1.687–4.869 0.0001
Tumour stage AJCC II vs III/IV 0.999 0.367 7.396 1 2.716 1.322–5.581 0.007
AJCC¼American Joint Committee on Cancer; d.f.¼degree of freedom. Significantly difference values are indicated in bold.
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searly tumour relapse and poor OS in pancreatic cancer. From a
functional point of view, this correlation could be explained by the
pro-tumourigenic capacities of ALCAM. Jezierska et al (2006)
discovered that ALCAM protected breast cancer cells against
apoptosis and autophagy. Choi et al (2000) showed that in
fibrosarcoma cell lines ALCAM augmented chemoresistance and
enhanced the metastatic potential. Lunter et al (2005) showed that
ALCAM regulated matrix metalloproteinase-2 in melanoma cell
lines, hence contributing to invasive tumour growth. In analogy,
one can speculate that the accumulation of ALCAM in pancreatic
tumour cells leads to similar tumour-promoting effects, therefore
having a negative prognostic impact.
However, our results as well as other studies are conflicting if
taking into account that reduced expression of ALCAM has also
been related to poor survival in some types of cancer (King et al,
2004; Mezzanzanica et al, 2008). Mezzanzanica et al (2008)
postulated that decreased expression of ALCAM in ovarian cancer
results from ALCAM delocalisation from the cell membrane to
cytoplasm, thus increasing the migratory properties of malignant
cells. In our study, we could show that in normal pancreatic tissue,
ALCAM is predominantly expressed in the cellular membrane,
whereas in pancreatic tumour cells, it is mainly localised in the
cytoplasm. Intriguingly, however, in the small subset of our clinical
specimen, exhibiting partly membranous expression in addition to
cytoplasmic expression, progression-free survival and OS was
significantly reduced in univariate analysis compared with patient
samples without any membranous expression. These results are in
accordance with previous findings in colorectal cancer (Weichert
et al, 2004), but contradict the assumption that the translocation of
ALCAM from the cellular membrane into the cytoplasm is its only
pivotal mechanism contributing to tumour promotion, and
therefore is associated with an adverse prognosis.
All in all, it still remains unanswered and a challenge to further
investigate (i) why in the majority of cancer entities examined so
far, overexpression of ALCAM is a negative prognostic marker,
whereas in some other tumour types its downregulation is
associated with an unfavourable prognosis and (ii) which role
plays the differential cellular localisation of ALCAM in tumour
progression and metastasation.
To obtain some deeper insight in the last mentioned question,
we examined a potential co-expression of ADAM17 and ALCAM in
pancreatic cancer. ADAM17 has been discovered to be an
important proteolytic sheddase of ALCAM (Bech-Serra et al,
2006). This mechanism can enhance tumour cell motility and
migratory capacity, hence increasing the invasive and metastatic
potential (Rosso et al, 2007). We could show that ADAM17 is
significantly overexpressed in pancreatic cancer compared with
normal pancreatic tissue. These findings in a large collective are
consistent with previous results including a smaller size of samples
(Ringel et al, 2006). But contrary to Ringel et al, we observed
ADAM17 mainly occurring in the cell cytoplasm and not in the
cellular membrane. These different observations are difficult to
explain, as we and Ringel et al employed similar methods of
immunohistochemistry and used the same type of ADAM17-
antibody. Yet, as our data are obtained from a much larger
collective of patient samples, they seem to be more valid by
statistical considerations. This study is the first to evaluate
ADAM17 as potential prognostic marker in a large number of
clinical specimens in pancreatic cancer. However, despite the
undoubtfully important role of ADAM17 in tumour disease
(Arribas et al, 2006; Ringel et al, 2006), our results cannot prove
ADAM17 to be a prognostic marker in pancreatic cancer. Nor, we
could observe a relevant co-expression between ALCAM and
ADAM17. Thus, to answer to what extent the proteolytic sheddase
of ALCAM by ADAM17 is a relevant step for tumour progression
in pancreatic cancer, further experimental studies are required.
Taken together, our data confirm the relevance of ALCAM as an
important predictor for clinical outcome in cancer. Learning more
about its biological functions in pancreatic cancer will help to gain
new insights into the pathogenesis of pancreatic cancer.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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